Atrium Therapeutics, Inc.

Atrium Therapeutics, Inc.

RNA·NASDAQ

$12.25

+0.81%
HealthcareBiotechnology

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the treatment of Duchenne Muscular Dystrophy; and AOC 1020 designed to treat facioscapulohumeral muscular dystrophy which are in preclinical stage. It also offers Lumizyme therapy for Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

At a Glance

Live Snapshot
Market Cap$209.54M
EPS-4.4800
P/E Ratio-3.29
Earnings Date09/02/2026

rna

Net Cash Provided by Financing Activities

Last Annual Value

42.57M

3-Year CAGR

-50%

5-Year CAGR

-31%

10-Year CAGR

24%

Atrium Therapeutics, Inc.

Atrium Therapeutics, Inc. Competitors Analysis of Net Cash Provided by Financing Activities

RNA · NASDAQ
CompanyNet Cash Provided by Financing Activities
CAGR 3Y
CAGR 5Y
CAGR 10Y
42.57M
-23.2%-24.7%N/A 
664.99M
303.4%N/A30.4%
MRNA logo
Moderna, Inc.
NASDAQ:MRNA
593.00M
N/AN/A2.3%
NUVL logo
Nuvalent, Inc.
NASDAQ:NUVL
515.34M
15.2%10.1%N/A
-873.38M
N/AN/AN/A
217.96M
43.1%5.5%N/A
524.46M
33.3%10.4%41.0%
-253.91M
N/AN/AN/A
255.98M
-24.5%8.4%33.3%
Atrium Therapeutics, Inc.

Atrium Therapeutics, Inc. Fair Value Envelope

RNA · NASDAQ

Our analysis suggests that RNA has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $12.25, this represents a potential HIDDEN relative to our calculated worth for Atrium Therapeutics, Inc..

Intrinsic Value
Current Price: $12.25